PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke
NCT04571177 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2026-04-13
Summary
Adult patients who are diagnosed with an acute supratentorial ischemic stroke within 48 hrs of onset will be enrolled into the study. Participants will undergo both a CT Scan and PET scan within 7 days of onset. Participants will have the option to undergo a second PET scan with fluorodeoxyglucose (FDG).
Conditions
- Acute Ischemic Stroke
Sponsors & Collaborators
-
University of Alberta
lead OTHER
Principal Investigators
-
Brian Buck · Associate Professor
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-01
- Primary Completion
- 2028-12-31
- Completion
- 2028-12-31
Countries
- Canada
Study Locations
More Related Trials
-
PET Imaging of Inflammation and Lipid Lowering Study
NCT04073797 ·Status: RECRUITING ·Phase: NA
-
18F-FSPG PET/CT Imaging in Patients With Cancers
NCT03144622 ·Status: UNKNOWN
-
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
NCT04316117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation
NCT01100671 ·Status: COMPLETED
-
Integrated PET/MR Imaging With Amino Acid Radiotracers in the Evaluation of Brain Neoplasms: Assessing Diagnostic Accuracy and Therapeutic Response
NCT07211360 ·Status: NOT_YET_RECRUITING
-
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
NCT05673031 ·Status: RECRUITING
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
NCT00935090 ·Status: RECRUITING
-
Correlation Between Various Adipokines and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) (18FDG-PET)
NCT01150006 ·Status: COMPLETED
-
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
NCT04804371 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
18F-AmBF3-TATE PET/CT for Imaging NET Patients
NCT04207762 ·Status: COMPLETED
-
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
NCT04552847 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology
NCT01180751 ·Status: UNKNOWN ·Phase: PHASE3
-
Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection
NCT05513027 ·Status: TERMINATED ·Phase: NA
-
68Ga-DOTA-TATE PET/CT Imaging in NETs
NCT04847505 ·Status: RECRUITING ·Phase: PHASE3
-
Fluorocholine PET/CT Basket Trial
NCT04150458 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis
NCT05762172 ·Status: COMPLETED ·Phase: NA
-
Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism
NCT02864810 ·Status: COMPLETED ·Phase: PHASE1
-
Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases
NCT05054998 ·Status: COMPLETED ·Phase: PHASE4
-
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
NCT03042416 ·Status: COMPLETED ·Phase: PHASE3
-
Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation
NCT03839706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors
NCT03883776 ·Status: COMPLETED ·Phase: PHASE1
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
Diagnostic Validity of [18F]GP1 PET for Diagnosing Acute Deep Vein Thrombosis
NCT04156230 ·Status: COMPLETED ·Phase: PHASE2
-
18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR
NCT02717572 ·Status: COMPLETED ·Phase: PHASE1
-
FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents
NCT02055586 ·Status: COMPLETED